QI LIANWEN has a total of 13 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2015. It filed its patents most often in WIPO (World Intellectual Property Organization), China and United States. Its main competitors in its focus markets measurement, pharmaceuticals and computer technology are LINCOLN MEMORIAL UNIV, YAN WENGUANG and SUNDREHAGEN ERLING.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | China | 5 | |
#3 | United States | 2 |
# | Industry | |
---|---|---|
#1 | Measurement | |
#2 | Pharmaceuticals | |
#3 | Computer technology |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Healthcare informatics |
# | Name | Total Patents |
---|---|---|
#1 | Qi Lianwen | 13 |
#2 | Zhu Wei | 12 |
#3 | Chen Yan | 12 |
#4 | Fan Yong | 8 |
#5 | Li Ping | 7 |
#6 | Qin Yong | 5 |
#7 | Zhao Yijing | 3 |
#8 | Zhang Lei | 1 |
#9 | Wei Tingting | 1 |
Publication | Filing date | Title |
---|---|---|
US2018088132A1 | Method of differentiating stable angina pectoris from acute coronary syndrome and diagnostic kit thereof | |
CN105651923A | Metabolic marker for diagnosing and distinguishing unstable angina pectoris and acute myocardial infarction | |
CN105486778A | Metabolism marker for diagnosis and distinguishing of stable angina pectoris and acute coronary syndrome | |
CN105445408A | Metabolite marker for diagnosing and distinguishing coronary atherosclerosis and stable angina pectoris | |
CN105486773A | Metabolic marker for diagnosing coronary heart disease | |
CN105424841A | Metabolic marker for diagnosis of coronary atherosclerosis |